Goldman Sachs on Viking Therapeutic (VKTX): 'we believe these results look encouraging'

September 22, 2026 1:07 PM

Goldman Sachs analyst Richard Law reiterated a Neutral rating and $38.00 price target on Viking Therapeutic (NASDAQ: VKTX).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found